Oncology and CNS Disorders

• Bryostatin 1, a protein kinase C antagonist, for Alzheimer's disease and Cognitive Disorders [U.S. Patents]

• Novel, non-toxic VDR affinity binding analogs of Vitamin D for prostate and other cancers [U.S. Patent Pending]

• Taxotere® and Taxotere®-MAb prodrugs for improved water solubility, oral bioavailability and targeted therapy [U.S. and Japanese Patents]

• Enhanced drug delivery formulations of natural anticancer drugs such as Taxosomes™, Dermos™, Camposomes™ and Bryosomes™ to increase efficacy, reduce toxicity and enhance quality-of-life [U.S., European and Japanese Patents]

• Developing supporting care therapies for cancer patients

• Manufacture the active ingredients of these formulations - paclitaxel, bryostatin-1 and other complex natural molecules - by a patented, cost-effective SuperFluids CXP™  technology

• Recently awarded a National Cancer Institute contract to manufacture and formulate a “difficult-to-manufacture and difficult-to-formulate” natural anticancer molecule, betulinic acid, for clinical trials against melanoma

Home l Company | Infectious Diseases | Oncology | Nutraceuticals | Product Pipeline | Purchase Products | Technology Platforms | Equipment |Patents | Press Releases | Contact Aphios